Λίστες Παρακ/θησης Ιδέες ProPicks AI Screener Εξερεύνηση δεδομένων Διαγράμματα Αποθηκευμένη εργασία

MedinCell S.A.

ENXTPA:MEDCL

Γαλλία / Υγεία / Φαρμακευτικά

Επισκόπ.

Μερίσματα

Κέρδη

Μοντέλα

Οικονομικές Καταστάσεις

Σύγκριση

Υγεία

Διαγράμματα

Ιστορικό οικ. καταστάσεων 10 ετ.

Τιμή μετοχής

14,80 EUR


Key Metrics	Latest
Total Revenue	13,2 M
Adjusted EBITDA	-18,81 M
EBITDA Margin	-142,5%
Net Profit Margin	-238,6%
Total Assets	58,863 M
Total Debt	69,194 M

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)		Mar-16	Mar-17	Mar-18	Mar-19	Mar-20	Mar-21	Mar-22	Mar-23	Mar-24	12 Months

Revenue	0	9	10	8	4	6	8	8	14	12	13
% Growth		NA	7.3%	-16.6%	-51.2%	48.3%	36.4%	1.9%	63.8%	-12.5%

Adjusted EBITDA	0	1	(3)	(6)	(15)	(18)	(18)	(23)	(23)	(20)	(19)
% Margin	NA	6.4%	-30.5%	-78.0%	-368.5%	-306.1%	-221.4%	-275.2%	-168.8%	-167.8%	-142.5%

Adjusted EBIT	0	0	(4)	(7)	(16)	(19)	(19)	(24)	(24)	(21)	(20)
% Margin	NA	4.5%	-36.1%	-83.9%	-383.2%	-319.6%	-231.2%	-285.6%	-175.9%	-175.3%	-148.3%

Adjusted Net Income	0	1	(4)	(9)	(19)	(24)	(21)	(25)	(32)	(25)	(31)
% Margin	NA	6.3%	-35.5%	-111.5%	-475.9%	-396.7%	-262.2%	-297.5%	-234.1%	-209.4%	-238.6%

Adjusted Basic EPS	NA	0.04	(0.25)	(0.64)	(1.12)	(1.18)	(0.97)	(1.00)	(1.27)	(0.88)	(1.06)

Υποστηρικτικοί υπολογισμοί

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Original
EUR	Fiscal Year Ending										Latest
(in millions)		Mar-16	Mar-17	Mar-18	Mar-19	Mar-20	Mar-21	Mar-22	Mar-23	Mar-24	Sep-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	0	9	10	8	4	6	8	8	14	12	13
% Growth	NA	NA	7.3%	-16.6%	-51.2%	48.3%	36.4%	1.9%	63.8%	-12.5%

Cost of Revenue	0	0	(1)	(0)	(0)	0	0	0	0	0	0
Gross Profit	0	9	9	8	4	6	8	8	14	12	13
% Revenue	NA	100.0%	91.1%	97.4%	98.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Research and Development	0	(6)	(8)	(9)	(12)	(17)	(20)	(24)	(28)	(21)	(20)
Selling and Marketing	0	(1)	(1)	(2)	(3)	(2)	(2)	(2)	(3)	(3)	(3)
General and Admin	0	(2)	(3)	(4)	(5)	(6)	(6)	(6)	(7)	(9)	(10)
Other Inc / (Exp)	0	0	(1)	(0)	(2)	(0)	3	1	(4)	0	(8)
Total Operating Exp	0	(9)	(13)	(16)	(22)	(25)	(24)	(31)	(42)	(33)	(41)

Operating Income	0	0	(4)	(7)	(18)	(19)	(15)	(23)	(28)	(21)	(28)
% Revenue	NA	4.6%	-36.2%	-89.4%	-436.7%	-323.2%	-188.7%	-275.9%	-205.9%	-174.9%	-209.4%

Interest Expense	0	(0)	(1)	(2)	(2)	(2)	(4)	(2)	(4)	(4)	(4)
Pre-tax Income	0	0	(5)	(9)	(20)	(21)	(19)	(25)	(32)	(25)	(31)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	1	(0)	0	(2)	0	0	0	(0)	(0)
Net Income to Company	0	1	(4)	(10)	(20)	(24)	(19)	(25)	(32)	(25)	(31)
% Margin	NA	6.3%	-35.5%	-115.3%	-486.3%	-398.6%	-231.9%	-297.5%	-234.4%	-209.6%	-238.2%

Minority Interest in Earnings	0	0	(0)	0	(0)	0	0	0	0	0	0
Net Income to Stockholders	0	1	(4)	(10)	(20)	(24)	(19)	(25)	(32)	(25)	(31)

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0	0	0	0

Net Income to Common	0	1	(4)	(10)	(20)	(24)	(19)	(25)	(32)	(25)	(31)
% Margin	NA	6.7%	-35.8%	-115.3%	-486.5%	-398.6%	-231.9%	-297.5%	-234.4%	-209.6%	-238.2%

As Reported
Basic EPS (Continuing Ops)	0.00	0.04	(0.25)	(0.66)	(1.14)	(1.19)	(0.86)	(1.00)	(1.27)	(0.88)	(1.09)
Diluted EPS (Continuing Ops)	0.00	0.04	(0.25)	(0.66)	(1.14)	(1.19)	(0.86)	(1.00)	(1.27)	(0.88)	(1.09)

WA Basic Shares Out.	0.00	14.55	14.41	14.43	17.26	20.11	22.03	24.84	25.19	28.42	29.66
WA Diluted Shares Out.	0.00	14.83	14.41	14.43	17.26	20.11	22.03	24.84	25.19	28.42	29.66

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	0	0	(5)	(9)	(20)	(21)	(19)	(25)	(32)	(25)	(31)
Addback: Net Interest Expense	0	0	1	2	2	2	4	2	4	4	4
Addback: Other Non Operating Expenses, Total	0	(0)	0	0	2	0	(0)	(1)	4	(0)	8
Addback: Depreciation & Amortization	0	0	1	0	1	1	1	1	1	1	1
Addback: Restructuring Charges	0	0	0	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	(0)	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	1	0	(3)	0	0	0	(0)
Adjusted EBITDA	0	1	(3)	(6)	(15)	(18)	(18)	(23)	(23)	(20)	(19)
% Margin	NA	6.4%	-30.5%	-78.0%	-368.5%	-306.1%	-221.4%	-275.2%	-168.8%	-167.8%	-142.5%

Adjusted EBIT	0	0	(4)	(7)	(16)	(19)	(19)	(24)	(24)	(21)	(20)
% Margin	NA	4.5%	-36.1%	-83.9%	-383.2%	-319.6%	-231.2%	-285.6%	-175.9%	-175.3%	-148.3%

Adjusted Net Income Reconciliation
Net Income to Company	0	1	(4)	(10)	(20)	(24)	(19)	(25)	(32)	(25)	(31)
Addback: Unusual Items	0	0	0	0	1	0	(3)	0	0	0	(0)
Less: Tax Benefit of Unusual Items (26%)	0	0	0	(0)	(0)	(0)	1	(0)	(0)	(0)	0
Adjusted Net Income	0	1	(4)	(9)	(19)	(24)	(21)	(25)	(32)	(25)	(31)
% Margin	NA	6.3%	-35.5%	-111.5%	-475.9%	-396.7%	-262.2%	-297.5%	-234.1%	-209.4%	-238.6%

Με επιφύλαξη παντός δικαιώματος. Όροι Χρήσης

Σφάλμα φόρτωσης

MedinCell S.A.

ENXTPA:MEDCL

Γαλλία / Υγεία / Φαρμακευτικά

Ιστορικό οικ. καταστάσεων 10 ετ.